Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic <i>BRAF</i> or <i>NRAS</i>-Mutated Melanoma Patients
Circulating tumour DNA (ctDNA) can be used to identify gene alterations. The purpose of this study was to determine whether the detection of ctDNA, based on the identification of <i>BRAF</i> and <i>NRAS</i> mutations before systemic treatment initiation, was associated with t...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/7/1871 |